Pete, when BPs partner for a drug, they look at its addressable market. Not just the current year, but years down the road. Biden said the US will have 300 million doses of vaccines by July. Will B-CV19 be approved before then? Highly unlikely.
Cases are trending down lately. Whether it’s due to vaccines remain to be seen. But we do know the high-risk populations are getting them first. Of those who decide not to get the vaccines this summer, how many will be sick enough to require B-CV19? The trial is targeting moderate-to-severe patients, but we know most have mild symptoms.
Yes I know not everyone will be vaccinated, but I believe most of the high-risk populations who might develop moderate-to-severe symptoms will. So investors need to ask themselves what’s the addressable market of B-CV19 if and when it’s approved. IMO herd immunity will be achieved by then. Good luck!
News 
Market Data 
Discover 
